Compare Novo Nordisk A/S (NVO) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Atlassian Corporation PLC — how do they compare? Novo Nordisk A/S trades at $38.12 (market cap $165.31B), while Atlassian Corporation PLC trades at $204.62 (market cap $51.53B). The key difference: Novo Nordisk A/S is far larger — about 3.2× Atlassian Corporation PLC's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Atlassian Corporation PLC for 64 Days on average.
| NVO | TEAM | |
|---|---|---|
Market Cap | $165.31B | $51.53B |
Volume | 11,432,838 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $63.98 | $203.57 |
52-Week Low | $35.29 | $57.15 |
Typical Hold Time | 116 Days | 64 Days |
Enterprise Value | $179.56B | $51.52B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat expectations, with Q2 2026 EPS of $0.96 surpassing the $0.82 estimate. The company maintains robust cash flow generation with $119.1B operating cash flow in 2025.
NVO presents compelling value with a 9.71 P/E ratio below industry averages and 59% analyst buy ratings. Upside potential exists to the $44.67 consensus target, though competition from Eli Lilly and FDA regulatory delays pose near-term risks. The obesity drug pipeline remains a key growth driver, supported by recent licensing deals totaling nearly $4B.
Atlassian (TEAM) trades at $195.67, up 0.87% with bullish technical momentum and strong analyst support. The stock shows consistent earnings beats with Q2 2026 EPS of $1.87 exceeding expectations. Revenue growth remains robust at $5.22B in 2025, though profitability challenges persist with negative net margins. Recent news highlights AI-driven growth catalysts and cloud migration success.
Outlook remains positive with 69.77% analyst buy ratings and $191.16 consensus target. Key opportunities include $140B addressable market and AI adoption, while risks involve negative profitability metrics and high valuation multiples. The stock faces execution risk in maintaining growth momentum amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
